SkylineDx Wins 2025 BioTech Breakthrough Award for “Diagnostics Company of the Year”

SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, and inflammatory and infectious diseases, announced it has been selected as “Diagnostics Company of the Year” in the fifth annual BioTech Breakthrough Awards program for its portfolio of genomic assay tests, including the Merlin CP-GEP Test for cutaneous melanoma and SKY92 test for multiple myeloma.

“At SkylineDx, we’re not just developing diagnostics – we’re changing how patients and doctors navigate critical treatment decisions together,” said Dharminder Chahal, CEO of SkylineDx. “Thank you to BioTech Breakthrough for this award, further validating our mission to improve patient quality of life by enabling them to benefit from personal insights at the genomic level of their disease, and helping all involved to make informed choices at pivotal moments in a patient’s life”.

[…]

“SkylineDx’s diagnostic solutions address a fundamental healthcare challenge,” said Bryan Vaughn, Managing Director, BioTech Breakthrough. “When melanoma is diagnosed, determining whether cancer cells have spread impacts treatment plans and patient survival. Patients need improved diagnostic systems to get the right treatments as soon as possible. SkylineDx’s multifaceted approach to molecular diagnostics, combined with its track record of translating academic discoveries into commercially viable products with high clinical utility, makes it our pick for ‘Diagnostics Company of the Year’ – SkylineDx bridges the gap between scientific innovation and effective healthcare solutions.”

Read more about SkylineDx on their website.

Date: December 4, 2025
Source: SkylineDx